Water

Water

SCHEMBL647336

BC#N.O.[NaH]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133917 1.00
SCHEMBL3648065 1.00
SCHEMBL331 1.00
SCHEMBL27509800 0.94
Hydrochloric Acid SCHEMBL7121633 0.94
SCHEMBL28305381 0.94
SCHEMBL1567 0.93
Water SCHEMBL645100 0.93
Hydrazine SCHEMBL6324276 0.88
Cyanide SCHEMBL2337100 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727279-B2 CENTRAL NERVOUS SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2004-04-27 US claimed
US-6469054-B1 PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR FOR THE TREATMENT OF CEREBRAL APOPLEXY, CRANIOCEREBRAL TRAUMA, PAIN AND SPASTICITY BAYER AKTIENGESELLSHAFT (DE) 2002-10-22 US claimed
WO-1996000391-A1 METHODS FOR THE SYNTHESIS OF DIKETOPIPERAZINES AFFYMAX TECHNOLOGIES N.V. (AN) 1996-01-04 WO claimed
EP-2989156-B1 PHYTOGLYCOGEN NANOPARTICLES AND METHODS OF MANUFACTURE THEREOF MIBELLE AG (CH) 2024-05-01 EP disclosed
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 EP disclosed
EP-4353719-A1 ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) 2024-04-17 EP disclosed
EP-3792258-B1 ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION SUZHOU CONNECT BIOPHARMACEUTICALS LTD (CN) 2024-02-07 EP disclosed
US-11883489-B2 Mucosal adjuvants and delivery systems THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2024-01-30 US disclosed
US-11732016-B2 Polypeptide exhibiting granulocyte-colony stimulating factor activity COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-08-22 US disclosed
US-20230050777-A1 ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION CONNECT BIOPHARMA HONGKONG LIMITED (HK) 2023-02-16 US disclosed
US-11512078-B2 Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) 2022-11-29 US disclosed
WO-1992008790-A1 CONJUGATES OF POLY(VINYLSACCHARIDE) WITH PROTEINS FOR THE STABILIZATION OF PROTEINS CARGILL, INCORPORATED (US) 1992-05-29 WO disclosed
WO-1992000748-A1 POLY(ALKYLENE OXIDE) AMINO ACID COPOLYMERS AND DRUG CARRIERS AND CHARGED COPOLYMERS BASED THEREON ENZON, INC. (US) 1992-01-23 WO disclosed
WO-1991005262-A1 BIOANALYTICAL DETECTION SYSTEM UNIVERSITY OF MICHIGAN (US) 1991-04-18 WO disclosed
US-4965279-A Thromboxane antagonist E. R. SQUIBB & SONS, INC. (US) 1990-10-23 US disclosed
US-4900685-A INDICATOR PARTICLES PRESENT IN BLOOD ARE MEASURED BY IMMUNOASSAYS; QUICK, SIMPLE CYTOSIGNET, INC. (US) 1990-02-13 US disclosed
EP-0345277-A1 ANALYTE DETECTION IN PARTICULATE-CONTAINING SAMPLES. CYTOSIGNET INC (US) 1989-12-13 EP disclosed
WO-1988005913-A1 ANALYTE DETECTION IN PARTICULATE-CONTAINING SAMPLES CYTOSIGNET, INC. (US) 1988-08-11 WO disclosed
US-4568687-A THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS AMERICAN CYANAMID COMPANY (US) 1986-02-04 US disclosed
EP-0000644-A2 Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-02-07 EP disclosed